Rockefeller Capital Management
NYMX

Rockefeller Capital Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Rockefeller Capital Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,000
Closed -$2K – 4153
2022
Q4 		$2K Buy
7,000
+5,000
+250% +$1.81K ﹤0.01% 3624
2022
Q3 		$0 Hold
2,000
– – ﹤0.01% 4535
2022
Q2 		$0 Hold
2,000
– – ﹤0.01% 4495
2022
Q1 		$2K Hold
2,000
– – ﹤0.01% 3670
2021
Q4 		$2K Hold
2,000
– – ﹤0.01% 3594
2021
Q3 		$4K Hold
2,000
– – ﹤0.01% 3283
2021
Q2 		$3K Hold
2,000
– – ﹤0.01% 3209
2021
Q1 		$4K Hold
2,000
– – ﹤0.01% 2989
2020
Q4 		$4K Hold
2,000
– – ﹤0.01% 2526
2020
Q3 		$4K Buy
+2,000
New +$5.82K ﹤0.01% 2309

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
CF
Corrigan Financial Middletown, Rhode Island $485M AUM 4.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's NYMX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2023, closing a stake of 7,000 shares — an estimated $2K sold.

Rockefeller Capital Management first reported a position in NYMX in Q3 2020 and held it in 10 quarters. The position peaked at $4K in Q3 2021. 35 funds tracked by Wall St. Rank hold NYMX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Nymox Pharmaceutical Corp position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 7,000 Nymox Pharmaceutical Corp shares in Q1 2023, an estimated $2K.
  • Rockefeller Capital Management first reported a position in Nymox Pharmaceutical Corp in Q3 2020 and held it in 10 quarters.
  • Rockefeller Capital Management's Nymox Pharmaceutical Corp position peaked at $4K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.